Insider Buying: AgomAb Therapeutics (NASDAQ:AGMB) CFO Purchases 10,000 Shares of Company Stock

Key Points

• AgomAb Therapeutics CFO Pierre Thadee Victor Kemula bought 10,000 shares at an average price of $8.59, investing $85,900 and increasing his ownership to 10,000 shares.
• AGMB shares opened at $8.84, up 1.7%, but remained near the lower end of their 12-month range of $7.97 to $17.82. The company recently reported a quarterly loss of $0.46 per share.
• Analyst sentiment is generally positive, with seven Buy ratings and one Hold rating, producing a “Moderate Buy” consensus and an average price target of $37.50, despite one recent Sell downgrade.

AgomAb Therapeutics NV (NASDAQ:AGMB - Get Free Report) CFO Pierre Thadee Victor Kemula bought 10,000 shares of the business's stock in a transaction that occurred on Tuesday, October 6th. The shares were bought at an average price of $8.59 per share, with a total value of $85,900.00. Following the completion of the purchase, the chief financial officer owned 10,000 shares in the company, valued at approximately $85,900. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

AgomAb Therapeutics Stock Up 1.7%

AgomAb Therapeutics stock opened at $8.84 on Wednesday. The business has a 50 day moving average price of $12.82 and a two-hundred day moving average price of $12.00. AgomAb Therapeutics NV has a 12 month low of $7.97 and a 12 month high of $17.82.

AgomAb Therapeutics (NASDAQ:AGMB - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.46) EPS for the quarter. Equities research analysts forecast that AgomAb Therapeutics NV will post -1.76 EPS for the current year.

Analyst Ratings Changes

Several research firms recently issued reports on AGMB. Piper Sandler began coverage on shares of AgomAb Therapeutics in a research report on Tuesday, August 25th. They issued an "overweight" rating and a $60.00 price target for the company. Cantor Fitzgerald initiated coverage on AgomAb Therapeutics in a report on Wednesday, August 19th. They set an "overweight" rating on the stock. HC Wainwright reissued a "buy" rating on shares of AgomAb Therapeutics in a report on Wednesday, September 16th. Wall Street Zen downgraded AgomAb Therapeutics from a "hold" rating to a "sell" rating in a research report on Sunday, September 27th. Finally, B. Riley Financial started coverage on AgomAb Therapeutics in a research note on Thursday, July 23rd. They issued a "buy" rating and a $34.00 price target on the stock. Seven research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $37.50.

About AgomAb Therapeutics

Agomab Therapeutics N.V. is a clinical-stage biotechnology company developing antibody-based medicines designed to activate biological pathways involved in tissue repair and regeneration. The company focuses on serious diseases in which restoring or rebuilding damaged tissue could provide therapeutic benefit.

Agomab's lead program, AGMB-129, is an investigational, gut-restricted agonist of fibroblast growth factor receptor 1c (FGFR1c) being developed for inflammatory bowel disease, including Crohn's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.